Xtl Biopharmaceuticals (XTLB) Short term Debt (2011 - 2025)
Xtl Biopharmaceuticals (XTLB) posted quarterly Short term Debt of $138000.0 for Q4 2025, little changed year-on-year from $138000.0 in Q4 2024, and little changed on a QoQ basis from $138000.0 in Q4 2024.
Xtl Biopharmaceuticals (XTLB) Short term Debt (2011 - 2025) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Short term Debt for 3 consecutive years, with $138000.0 the latest figure, recorded in Q4 2025.
- Quarterly Short term Debt changed 0.0% year-over-year to $138000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $138000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $138000.0, changed 0.0% from the prior year.
- Short term Debt steadied at $138000.0 in Q4 2025 per XTLB's latest filing, from $138000.0 in the prior quarter.
- Over the last five years, Short term Debt for XTLB reached as high as $138000.0 in Q4 2024 and fell as low as $138000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn |
| 10 | Xtl Biopharmaceuticals | 2.51 Bn | 2.51 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 138,000.00 |
| Dec 31, 2024 | 138,000.00 |
| Dec 31, 2011 | 26,000.00 |